Seek Returns logo

Command Palette

Search for a command to run...

JNJ vs. RHHVF: A Head-to-Head Stock Comparison

Here's a clear look at JNJ and RHHVF, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolJNJRHHVF
Company NameJohnson & JohnsonRoche Holding AG
CountryUnited StatesSwitzerland
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization579.46 billion USD313.72 billion USD
CurrencyUSDUSD
ExchangeNYSEOTC Markets OTCQX
Listing DateJanuary 2, 1962February 13, 2009
Security TypeCommon StockCommon Stock

JNJ's market capitalization (579.46 billion USD) is substantially larger than RHHVF's (313.72 billion USD), indicating a significant difference in their market valuations.

Historical Performance

This chart compares the performance of JNJ and RHHVF by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

JNJ vs. RHHVF: Growth of a $10,000 investment over the past five years.

Historical Performance at a Glance

SymbolJNJRHHVF
5-Day Price Return2.14%3.86%
13-Week Price Return16.85%--
26-Week Price Return38.02%--
52-Week Price Return47.40%--
Month-to-Date Return-3.21%-1.23%
Year-to-Date Return16.19%-1.23%
10-Day Avg. Volume8.19M0.88M
3-Month Avg. Volume8.96M0.88M
3-Month Volatility15.82%--
Beta0.351.46

RHHVF carries a higher beta at 1.46, indicating it's more sensitive to market moves, while JNJ (beta: 0.35) exhibits greater stability.

Profitability

Return on Equity (TTM)

JNJ

33.78%

Pharmaceuticals Industry

Max
39.28%
Q3
20.27%
Median
12.92%
Q1
6.34%
Min
-14.55%

In the upper quartile for the Pharmaceuticals industry, JNJ's Return on Equity of 33.78% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

RHHVF

--

Pharmaceuticals Industry

Max
39.28%
Q3
20.27%
Median
12.92%
Q1
6.34%
Min
-14.55%

Return on Equity data for RHHVF is currently unavailable.

JNJ vs. RHHVF: A comparison of their Return on Equity (TTM) against the Pharmaceuticals industry benchmark.

Net Profit Margin (TTM)

JNJ

28.46%

Pharmaceuticals Industry

Max
41.87%
Q3
22.21%
Median
14.64%
Q1
9.09%
Min
-8.35%

A Net Profit Margin of 28.46% places JNJ in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

RHHVF

--

Pharmaceuticals Industry

Max
41.87%
Q3
22.21%
Median
14.64%
Q1
9.09%
Min
-8.35%

Net Profit Margin data for RHHVF is currently unavailable.

JNJ vs. RHHVF: A comparison of their Net Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Operating Profit Margin (TTM)

JNJ

34.59%

Pharmaceuticals Industry

Max
42.93%
Q3
25.68%
Median
18.69%
Q1
12.70%
Min
-4.35%

An Operating Profit Margin of 34.59% places JNJ in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

RHHVF

--

Pharmaceuticals Industry

Max
42.93%
Q3
25.68%
Median
18.69%
Q1
12.70%
Min
-4.35%

Operating Profit Margin data for RHHVF is currently unavailable.

JNJ vs. RHHVF: A comparison of their Operating Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Profitability at a Glance

SymbolJNJRHHVF
Return on Equity (TTM)33.78%--
Return on Assets (TTM)13.76%--
Net Profit Margin (TTM)28.46%--
Operating Profit Margin (TTM)34.59%--
Gross Profit Margin (TTM)67.92%--

Financial Strength

Current Ratio (MRQ)

JNJ

1.03

Pharmaceuticals Industry

Max
6.79
Q3
3.64
Median
2.17
Q1
1.38
Min
0.80

JNJ's Current Ratio of 1.03 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

RHHVF

--

Pharmaceuticals Industry

Max
6.79
Q3
3.64
Median
2.17
Q1
1.38
Min
0.80

Current Ratio data for RHHVF is currently unavailable.

JNJ vs. RHHVF: A comparison of their Current Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Debt-to-Equity Ratio (MRQ)

JNJ

0.59

Pharmaceuticals Industry

Max
1.60
Q3
0.76
Median
0.28
Q1
0.03
Min
0.00

JNJ's Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

RHHVF

--

Pharmaceuticals Industry

Max
1.60
Q3
0.76
Median
0.28
Q1
0.03
Min
0.00

Debt-to-Equity Ratio data for RHHVF is currently unavailable.

JNJ vs. RHHVF: A comparison of their Debt-to-Equity Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Interest Coverage Ratio (TTM)

JNJ

34.01

Pharmaceuticals Industry

Max
154.61
Q3
67.33
Median
13.25
Q1
2.96
Min
-27.02

JNJ's Interest Coverage Ratio of 34.01 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

RHHVF

--

Pharmaceuticals Industry

Max
154.61
Q3
67.33
Median
13.25
Q1
2.96
Min
-27.02

Interest Coverage Ratio data for RHHVF is currently unavailable.

JNJ vs. RHHVF: A comparison of their Interest Coverage Ratio (TTM) against the Pharmaceuticals industry benchmark.

Financial Strength at a Glance

SymbolJNJRHHVF
Current Ratio (MRQ)1.03--
Quick Ratio (MRQ)0.69--
Debt-to-Equity Ratio (MRQ)0.59--
Interest Coverage Ratio (TTM)34.01--

Growth

Revenue Growth

JNJ vs. RHHVF: A comparison of their Revenue Growth across different time periods.

Revenue Growth at a Glance

SymbolJNJRHHVF
Revenue Growth (MRQ vs Prior YoY)9.08%--
Revenue Growth (TTM vs Prior YoY)6.05%--
3-Year Revenue CAGR5.60%--
5-Year Revenue CAGR2.67%--

EPS Growth

JNJ vs. RHHVF: A comparison of their EPS Growth across different time periods.

EPS Growth at a Glance

SymbolJNJRHHVF
EPS Growth (MRQ vs Prior YoY)48.50%--
EPS Growth (TTM vs Prior YoY)90.56%--
3-Year EPS CAGR17.88%--
5-Year EPS CAGR14.90%--

Dividend

Dividend Yield (TTM)

JNJ

2.14%

Pharmaceuticals Industry

Max
6.35%
Q3
3.00%
Median
1.84%
Q1
0.00%
Min
0.00%

JNJ's Dividend Yield of 2.14% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

RHHVF

0.00%

Pharmaceuticals Industry

Max
6.35%
Q3
3.00%
Median
1.84%
Q1
0.00%
Min
0.00%

RHHVF currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

JNJ vs. RHHVF: A comparison of their Dividend Yield (TTM) against the Pharmaceuticals industry benchmark.

Dividend Payout Ratio (TTM)

JNJ

46.19%

Pharmaceuticals Industry

Max
188.03%
Q3
80.63%
Median
44.08%
Q1
0.00%
Min
0.00%

JNJ's Dividend Payout Ratio of 46.19% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RHHVF

0.00%

Pharmaceuticals Industry

Max
188.03%
Q3
80.63%
Median
44.08%
Q1
0.00%
Min
0.00%

RHHVF has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

JNJ vs. RHHVF: A comparison of their Dividend Payout Ratio (TTM) against the Pharmaceuticals industry benchmark.

Dividend at a Glance

SymbolJNJRHHVF
Dividend Yield (TTM)2.14%0.00%
Dividend Payout Ratio (TTM)46.19%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

JNJ

21.62

Pharmaceuticals Industry

Max
40.21
Q3
26.28
Median
18.77
Q1
14.14
Min
3.46

JNJ's P/E Ratio of 21.62 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

RHHVF

--

Pharmaceuticals Industry

Max
40.21
Q3
26.28
Median
18.77
Q1
14.14
Min
3.46

P/E Ratio data for RHHVF is currently unavailable.

JNJ vs. RHHVF: A comparison of their Price-to-Earnings Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Sales Ratio (TTM)

JNJ

6.15

Pharmaceuticals Industry

Max
7.19
Q3
4.85
Median
2.51
Q1
1.94
Min
0.83

JNJ's P/S Ratio of 6.15 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

RHHVF

--

Pharmaceuticals Industry

Max
7.19
Q3
4.85
Median
2.51
Q1
1.94
Min
0.83

P/S Ratio data for RHHVF is currently unavailable.

JNJ vs. RHHVF: A comparison of their Price-to-Sales Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Book Ratio (MRQ)

JNJ

6.13

Pharmaceuticals Industry

Max
10.12
Q3
5.02
Median
2.39
Q1
1.54
Min
0.63

JNJ's P/B Ratio of 6.13 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company's net assets, a valuation that hinges on its ability to generate superior profits.

RHHVF

--

Pharmaceuticals Industry

Max
10.12
Q3
5.02
Median
2.39
Q1
1.54
Min
0.63

P/B Ratio data for RHHVF is currently unavailable.

JNJ vs. RHHVF: A comparison of their Price-to-Book Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Valuation at a Glance

SymbolJNJRHHVF
Price-to-Earnings Ratio (TTM)21.62--
Price-to-Sales Ratio (TTM)6.15--
Price-to-Book Ratio (MRQ)6.13--
Price-to-Free Cash Flow Ratio (TTM)29.42--